Celularity Inc

Celularity Inc., which trades under the ticker GXGX, is a clinical-stage biotechnology company focused on allogeneic cell therapy, having entered the public markets through GX Acquisition Corp. II, a blank-check company that completed its IPO in January 2021. The SPAC was sponsored by GX Sponsor II LLC, an affiliate of GX Capital Management. The business combination between GX Acquisition Corp. II and Celularity closed in mid-2021, positioning the combined entity in the healthcare and life sciences sector with a focus on placenta-derived cell therapeutics. Celularity filed an 8-K current report with the SEC on December 19, 2025, disclosing a material corporate event. Visit SpacDesk and sign up for full access to Celularity's filing history, sponsor details, and post-merger performance data.